Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

The acquisition, announced in February, underscores Novo Nordisk’s push to boost output of its popular obesity drug Wegovy.

Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...

also known as Mounjaro — that so far has shown even more weight loss than Wegovy. A pack of other companies are hot on both ...

once-daily obesity pill from Eccogene a year ago for up to $2 billion, it said it believed the treatment could cause fewer ...

Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy ...